ArticleAddiction biology2026
Alcohol Use Disorder With Metabolic Dysfunction Is Associated With Adverse Health Impacts in a United States Clinical Setting.
Article in Addiction biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction.Biological psychiatry global open science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The combined disease burden of excessive alcohol consumption and metabolic dysfunction (MD) is an escalating global concern. Although it is well established that both factors adversely impact health, the biological characteristics and comorbidities of their overlap remain understudied in the United States. The present study investigated whether concurrent MD and alcohol use disorder (AUD) is associated with worse liver-related and psychiatric health. A total of 1220 participants were recruited through the Natural History Protocol at the National Institutes of Health (NIH) and categorized into the following four groups: healthy controls (HC), individuals with MD (metHC), individuals with current AUD without MD (AUD) and those with both current AUD and MD (metAUD). Sociodemographic and clinical biomarkers, liver injury indices (Fibrosis-4 [FIB-4], LiverRisk, NAFLD fibrosis score [NFS]), liver enzymes and inflammatory markers (GGT, AST, ALT, CRP), liver function tests (albumin, bilirubin, PT-INR), psychiatric and substance use comorbidities as well as current smoking were assessed in the four groups using analysis of covariance (ANCOVA). In addition, the clinical biomarkers were compared across three groups: mild (< 3 MD criteria) and severe (≥ 3) metAUD, as well as AUD only. Liver enzymes, noninvasive liver fibrosis scores and liver function tests showed additive effects across metHC, AUD and metAUD compared to HC, with the largest effects in metAUD for GGT, AST, ALT, CRP, albumin, direct bilirubin, FIB-4, LiverRisk and NFS (p < 0.001). Psychiatric disorders also exhibited the most significant association with metAUD (p < 0.001). Within AUD, greater MD severity was associated with higher GGT, ALT, CRP, NFS and any DSM anxiety disorders (p < 0.05). These findings suggest that MD in the context of AUD is associated with greater liver dysfunction and psychiatric burden, supporting MD-targeted treatment strategies in clinical care for AUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.